DOCSLIB.ORG

Procurement Procedure Ref. EMA/2014/01/PH Annex VII-A Substances and Related Substance Groups

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Procurement Procedure Ref. EMA/2014/01/PH Annex VII-A Substances and Related Substance Groups Technical Specifications for open invitation to tender: Procurement procedure ref. EMA/2014/01/PH Annex VII-A Substances and related substance groups ID Substance Group Substances 1 PARACETAMOL ACETYLCYSTEINE, PARACETAMOL 1 PARACETAMOL ASCORBIC ACID, DIMETOFRINE, ISOPROPAMIDE IODIDE, PARACETAMOL, ANHYDROUS CAFFEINE, CHLORPHENIRAMINE MALEATE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, ACETYLSALICYLIC ACID 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, CAFFEINE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, CHLORPHENIRAMINE MALEATE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, PHENYLEPHRINE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, PROPYPHENAZONE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, PSEUDOEPHEDRINE SULPHATE 1 PARACETAMOL ASCORBIC ACID, PARACETAMOL, SODIUM BICARBONATE, POTASSIUM BICARBONATE, SODIUM CARBONATE ANHYDROUS, ANHYDROUS CITRIC ACID 1 PARACETAMOL BROMPHENIRAMINE MALEATE, ASCORBIC ACID, PARACETAMOL, CAFFEINE 1 PARACETAMOL BROMPHENIRAMINE MALEATE, PARACETAMOL, CAFFEINE 1 PARACETAMOL BUCLIZINE HYDROCHLORIDE, DOCUSATE SODIUM, PARACETAMOL, CODEINE PHOSPHATE 1 PARACETAMOL BUCLIZINE HYDROCHLORIDE, PARACETAMOL, CODEINE PHOSPHATE 1 PARACETAMOL CARBASALATE CALCIUM, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, ASCORBIC ACID, ISOPROPAMIDE IODIDE, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, ASCORBIC ACID, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE MALEATE, ASCORBIC ACID, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, ASCORBIC ACID, PARACETAMOL, CAFFEINE CITRATE 1 PARACETAMOL CHLORPHENAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE MALEATE, ISOPROPAMIDE IODIDE, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE MALEATE, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PARACETAMOL, PSEUDOEPHEDRINE SULPHATE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PARACETAMOL, SALICYLAMIDE, ANHYDROUS CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PARACETAMOL, SODIUM ASCORBATE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE MALEATE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL PH. EUR. 1 PARACETAMOL CHLORPHENAMINE MALEATE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE, PARACETAMOL 1 PARACETAMOL CHLORPHENAMINE, PARACETAMOL, CAFFEINE 1 PARACETAMOL CHLORPHENAMINE, PARACETAMOL, PHENYLEPHRINE 1 PARACETAMOL CHLORPHENAMINE, PARACETAMOL, PSEUDOEPHEDRINE 1 PARACETAMOL CODEINE PHOSPHATE BP, PARACETAMOL PH. EUR. 1 PARACETAMOL CODEINE PHOSPHATE HEMIHYDRATE, PARACETAMOL DC 1 PARACETAMOL CODEINE PHOSPHATE SESQUIHYDRATE, PARACETAMOL 1 PARACETAMOL CODEINE PHOSPHATE SESQUIHYDRATE, PARACETAMOL, PROPYPHENAZONE, CAFFEINE 1 PARACETAMOL CYANOCOBALAMIN, PARACETAMOL, THIAMINE NITRATE, PYRIDOXINE HYDROCHLORIDE 1 PARACETAMOL DEXCHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXCHLORPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PARACETAMOL, EPHEDRINE SULFATE 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL, DOXYLAMINE HYDROGEN SUCCINATE, EPHEDRINE SULFATE 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL, PHENYLPROPANOLAMINE HYDROCHLORIDE 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PARACETAMOL, PSEUDOEPHEDRINE SULPHATE 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PROMETHAZINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, ASCORBIC ACID, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN, PARACETAMOL Page 1 of 69 ID Substance Group Substances 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL, CHLORPHENIRAMINE MALEATE 1 PARACETAMOL DEXTROMETHORPHAN, PARACETAMOL, PSEUDOEPHEDRINE 1 PARACETAMOL DEXTROPROPOXYPHENE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DEXTROPROPOXYPHENE, PARACETAMOL, CAFFEINE 1 PARACETAMOL DICLOFENAC SODIUM, PARACETAMOL 1 PARACETAMOL DIHYDROCODEINE TARTRATE, PARACETAMOL 1 PARACETAMOL DIHYDROCODEINE TARTRATE, PARACETAMOL, GELATINE 1 PARACETAMOL DIMENHYDRINATE, PARACETAMOL, CAFFEINE 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL, CAFFEINE, EPHEDRINE HYDROCHLORIDE 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE, CAFFEINE, PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR. 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL DIPHENHYDRAMINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE, PARACETAMOL, PHOLCODINE 1 PARACETAMOL DOXYLAMINE SUCCINATE, PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE 1 PARACETAMOL DOXYLAMINE SUCCINATE, PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE 1 PARACETAMOL DROTAVERINE HYDROCHLORIDE, PARACETAMOL, CODEINE PHOSPHATE 1 PARACETAMOL DROTAVERINE HYDROCHLORIDE, PARACETAMOL, CODEINE PHOSPHATE HEMIHYDRATE 1 PARACETAMOL ERGOTAMINE TARTRATE, PARACETAMOL, BELLADONNA ALKALOIDS, CAFFEINE 1 PARACETAMOL GUAIFENESIN, PARACETAMOL 1 PARACETAMOL GUAIFENESIN, PARACETAMOL, CAFFEINE 1 PARACETAMOL IBUPROFEN, PARACETAMOL 1 PARACETAMOL ISOMETHEPTENE MUCATE, PARACETAMOL 1 PARACETAMOL LIDOCAINE HCL, PARACETAMOL 1 PARACETAMOL METAMIZOLE SODIUM, PARACETAMOL, PHENOBARBITAL, CAFFEINE, CODEINE PHOSPHATE HEMIHYDRATE 1 PARACETAMOL METAMIZOLE, PARACETAMOL, CAFFEINE, CODEINE PHOSPHATE 1 PARACETAMOL METHOCARBAMOL, PARACETAMOL 1 PARACETAMOL METOCLOPRAMIDE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL METOCLOPRAMIDE, PARACETAMOL 1 PARACETAMOL ORPHENADRINE CITRATE, PARACETAMOL 1 PARACETAMOL OXYCODONE HYDROCHLORIDE, PARACETAMOL 1 PARACETAMOL PARACETAMOL 1 PARACETAMOL PARACETAMOL DC 1 PARACETAMOL PARACETAMOL PH. EUR. 1 PARACETAMOL PARACETAMOL PH. EUR., CODEINE PHOSPHATE PH.EUR.
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Commission Decision of 8 February 2010 Concerning The
    L 36/36 EN Official Journal of the European Union 9.2.2010 COMMISSION DECISION of 8 February 2010 concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (notified under document C(2010) 751) (Text with EEA relevance) (2010/72/EU) THE EUROPEAN COMMISSION, concerned should therefore not be included in Annex I, IA or IB to Directive 98/8/EC. Having regard to the Treaty on the Functioning of the European Union, (6) In the interest of legal certainty, biocidal products Having regard to Directive 98/8/EC of the European Parliament containing active substances for the product-types and of the Council of 16 February 1998 concerning the placing indicated in the Annex to this Decision should no of biocidal products on the market ( 1), and in particular the longer be placed on the market, with effect from a second subparagraph of Article 16(2) thereof, specific date. Whereas: (7) The measures provided for in this Decision are in accordance with the opinion of the Standing (1) Commission Regulation (EC) No 1451/2007 of Committee on Biocidal Products, 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive HAS ADOPTED THIS DECISION: 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the Article 1 market ( 2) establishes a list of active substances to be assessed, with a view to their possible inclusion in The substances indicated in the Annex to this Decision shall not Annex I, IA or IB to Directive 98/8/EC.
    [Show full text]
  • Betamethasone
    Betamethasone Background Betamethasone is a potent, long-acting, synthetic glucocorticoid widely used in equine veterinary medicine as a steroidal anti-inflammatory.1 It is often administered intra-articularly for control of pain associated with inflammation and osteoarthritis.2 Betamethasone is a prescription medication and can only be dispensed from or upon the request of a http://en.wikipedia.org/wiki/Betamethasone#/media/File:Betamethasone veterinarian. It is commercially available .png in a variety of formulations including BetaVet™, BetaVet Soluspan Suspension® and Betasone Aqueous Suspension™.3 Betamethasone can be used intra-articularly, intramuscularly, by inhalation, and topically.4 When administered intra-articularly, it is often combined with other substances such as hyaluronan.5 Intra-articular and intramuscular dosages range widely based upon articular space, medication combination protocol, and practitioner preference. Betamethasone is a glucocorticoid receptor agonist which binds to various glucocorticoid receptors setting off a sequence of events affecting gene transcription and the synthesis of proteins. These mechanisms of action include: • Potential alteration of the G protein-coupled receptors to interfere with intracellular signal transduction pathways • Enhanced transcription in many genes, especially those involving suppression of inflammation. • Inhibition of gene transcription – including those that encode pro-inflammatory substances. The last two of these are considered genomic effects. This type of corticosteroid effect usually occurs within hours to days after administration. The genomic effects persist after the concentrations of the synthetic corticosteroid in plasma are no longer detectable, as evidenced by persistent suppression of the normal production of hydrocortisone following synthetic corticosteroid administration.6 When used judiciously, corticosteroids can be beneficial to the horse.
    [Show full text]
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • Contact Allergy to Aluminium Siemund, Ingrid
    Contact allergy to aluminium Siemund, Ingrid 2017 Document Version: Publisher's PDF, also known as Version of record Link to publication Citation for published version (APA): Siemund, I. (2017). Contact allergy to aluminium. Lund University: Faculty of Medicine. Total number of authors: 1 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 INGRID SIEMUND INGRID Contact allergy to aluminium Contact allergy to aluminium INGRID SIEMUND | DEPARTMENT OF OCCUPATIONAL AND ENVIRONMENTAL DERMATOLOGY | SKÅNE UNIVERSITY HOSPITAL, LUND UNIVERSITY 9 Department of Occupational and 789176 Environmental Dermatology Lund University, Faculty of Medicine 2017:113 Doctoral Dissertation Series 2017:113 194959 ISBN 978-91-7619-495-9 ISSN 1652-8220 Contact allergy to aluminium 1 2 Contact allergy to aluminium Ingrid Siemund DOCTORAL DISSERTATION by due permission of the Faculty of Medicine, Lund University, Sweden.
    [Show full text]
  • Theophylline-7-Acetic Acid
    Theophylline-7-acetic acid sc-237085 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Theophylline-7-acetic acid STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH2 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C9-H10-N4-O4, "purine-7-acetic acid, 1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxo-", acefylline, acephylline, 7-(carboxymethyl)theophylline, "1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxopurine-7-acetic acid", "7-theophyllineacetic acid", "7-theophyllinylacetic acid", alkaloid Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 1 Toxicity: 2 Body Contact: 2 Min/Nil=0 Low=1 Reactivity: 1 Moderate=2 High=3 Chronic: 2 Extreme=4 1 of 8 CANADIAN WHMIS SYMBOLS EMERGENCY OVERVIEW RISK Harmful if swallowed. Irritating to eyes, respiratory system and skin. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. ! Xanthine derivatives may produce nausea, vomiting, anorexia, stomach pain, vomiting of blood and diarrhea. Protein in the urine, increased amounts of urine output, and increased excretion of renal tubular cells and red blood cells may also occur.
    [Show full text]